KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares RepurchasedShort-Term Debt repayments
Ratios

Pacira BioSciences (PCRX) EBIAT (2016 - 2025)

Pacira BioSciences (PCRX) has 16 years of EBIAT data on record, last reported at $1.6 million in Q4 2025.

  • For Q4 2025, EBIAT fell 89.79% year-over-year to $1.6 million; the TTM value through Dec 2025 reached $7.0 million, up 107.07%, while the annual FY2025 figure was $7.0 million, 107.07% up from the prior year.
  • EBIAT reached $1.6 million in Q4 2025 per PCRX's latest filing, down from $5.4 million in the prior quarter.
  • Across five years, EBIAT topped out at $25.8 million in Q2 2023 and bottomed at -$143.5 million in Q3 2024.
  • Average EBIAT over 5 years is $365900.0, with a median of $7.9 million recorded in 2022.
  • Peak YoY movement for EBIAT: soared 1666.81% in 2023, then crashed 1421.29% in 2024.
  • A 5-year view of EBIAT shows it stood at -$5.1 million in 2021, then tumbled by 96.92% to -$10.1 million in 2022, then soared by 346.19% to $24.9 million in 2023, then crashed by 35.5% to $16.0 million in 2024, then crashed by 89.79% to $1.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBIAT were $1.6 million in Q4 2025, $5.4 million in Q3 2025, and -$4.8 million in Q2 2025.